GVI
ALNY icon

Green Valley Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Green Valley Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-168,864
Closed -$14.8M – 33
2018
Q3 		$14.8M Sell
168,864
-13,447
-7% -$1.35M 0.66% 31
2018
Q2 		$18M Buy
182,311
+37,211
+26% +$3.69M 0.84% 31
2018
Q1 		$17.3M Buy
+145,100
New +$18.7M 0.82% 30

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Green Valley Investors's ALNY Position: Q4 2018 in Review

Green Valley Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 168,864 shares — an estimated $14.8M sold.

Green Valley Investors first reported a position in ALNY in Q1 2018 and held it in 3 quarters. The position peaked at $18M in Q2 2018. 283 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Green Valley Investors reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Green Valley Investors sold 168,864 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $14.8M.
  • Green Valley Investors first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Green Valley Investors's Alnylam Pharmaceuticals position peaked at $18M in Q2 2018.
  • 283 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Green Valley Investors's 13F filing for Q4 2018, filed 13 Feb 2019.